Numerous studies targeting TGFβ in various experimental diseases have yielded favourable results, but recent clinical trials have questioned efficacy of available interventions in human CKD (Akhurst and Hata 2012; Muñoz-Félix et al. 2015) (Clinicaltrial.gov numbers NCT00464321 and NCT01113801). Here, TGFB1 is linked to chronic kidney disease.